Efficacy and Safety of Tideglusib in Congenital Myotonic Dystrophy
Status:
Recruiting
Trial end date:
2022-03-01
Target enrollment:
Participant gender:
Summary
This is a randomized, multicenter, double-blind, placebo-controlled, Phase 2/3 study of
patients (aged 6 to 16 years) diagnosed with Congenital Myotonic Dystrophy (Congenital DM1).